- Home
- IMCR vs PAYO Comparison
IMCR vs PAYO Comparison
Compare IMCR & PAYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PAYO
- Stock Information
- Founded
- IMCR 2008
- PAYO 2005
- Country
- IMCR United Kingdom
- PAYO United States
- Employees
- IMCR N/A
- PAYO N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PAYO EDP Services
- Sector
- IMCR Health Care
- PAYO Technology
- Exchange
- IMCR Nasdaq
- PAYO Nasdaq
- Market Cap
- IMCR 1.8B
- PAYO 2.7B
- IPO Year
- IMCR 2021
- PAYO N/A
- Fundamental
- Price
- IMCR $33.42
- PAYO $6.64
- Analyst Decision
- IMCR Buy
- PAYO Strong Buy
- Analyst Count
- IMCR 9
- PAYO 8
- Target Price
- IMCR $57.00
- PAYO $10.06
- AVG Volume (30 Days)
- IMCR 280.0K
- PAYO 2.9M
- Earning Date
- IMCR 11-05-2025
- PAYO 11-04-2025
- Dividend Yield
- IMCR N/A
- PAYO N/A
- EPS Growth
- IMCR N/A
- PAYO N/A
- EPS
- IMCR N/A
- PAYO 0.25
- Revenue
- IMCR $356,145,000.00
- PAYO $1,017,244,000.00
- Revenue This Year
- IMCR $29.67
- PAYO $9.34
- Revenue Next Year
- IMCR $11.12
- PAYO $7.48
- P/E Ratio
- IMCR N/A
- PAYO $26.46
- Revenue Growth
- IMCR 26.78
- PAYO 13.02
- 52 Week Low
- IMCR $23.15
- PAYO $5.71
- 52 Week High
- IMCR $39.33
- PAYO $11.29
- Technical
- Relative Strength Index (RSI)
- IMCR 44.21
- PAYO 48.39
- Support Level
- IMCR $35.33
- PAYO $6.44
- Resistance Level
- IMCR $36.76
- PAYO $6.91
- Average True Range (ATR)
- IMCR 1.57
- PAYO 0.22
- MACD
- IMCR -0.20
- PAYO -0.01
- Stochastic Oscillator
- IMCR 24.65
- PAYO 33.06
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.